NCT03504410 2023-02-08Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AMLCornerstone PharmaceuticalsPhase 3 Terminated200 enrolled 9 charts
NCT01520805 2016-12-29Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic SyndromeCornerstone PharmaceuticalsPhase 2 Withdrawn